中國TreatyWIPO
2022年2月11日

China Joins Two WIPO Treaties, the Hague System and the Marrakesh Treaty

Snow Pine painted by artist Evelyn Hui, mother of Eagle IP’s founder Dr. Jacqueline Lui

It has been two challenging years, yet there are many reasons to still have hope. We wish you a blessed Lunar New Year as we welcome the year of the Tiger.

We wanted to highlight a few new developments in China.

China has joined the Hague System for the International Registration of Industrial Designs, submitting its instrument of accession to the 1999 Geneva Act of the Hague Agreement on February 5, 2022. The Act will go into effect in China on May 5, 2022.

The Hague System provides a way for designers to file a single international design application to register up to 100 designs in up to 94 countries. This helps applicants save time and money on filing separately applications in each jurisdiction. Applicants don’t need to file a national or regional design application first. They can just directly file an international application in the Hague System in one language with one set of fees.

China joining the Hague System gives international designers the option to obtain design patent rights in China through the streamlined Hague System. Chinese designers likewise will have access to the Hague System and access to streamlined design registration in 90+ countries.

As part of this process, China has been updating its design patent laws to comply with Hague System requirements, most notably increasing design patent protection life from 10 years to 15 years in the newest 4th Amendment of the Patent Law. Full details will be available in May. Please note that Hong Kong and Macau are not included.

On the same day, China also signed onto the Marrakesh Treaty, a humanitarian treaty aimed at removing copyright barriers to providing visual impaired people access to published works. The Marrakesh Treaty was adopted on June 27, 2013 and is also administered by the World Intellectual Property Organization (WIPO). It currently has 84 contracting parties, including China, the US, and the European Union.

Eagle IP are experts in patent law and we offer a one-stop service for your global IP needs.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

About the Authors

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

Inventive Step for an Enantiomer over a Racemate: “L-ornidazole” Patent Invalidation Case

2023年11月27日
Each year, China’s Supreme People’s Court (SPC) issues its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in the previous year. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]

A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case

2026年2月27日
Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions. As therapeutics move away from the traditional “one-size-fits-all” model, unique challenges are presented in the patent examination process. The 2024 Top 10 Patent Re-examination and Invalidation case highlighted below provides further insight into how the […]

A More Detailed Overview of China’s Patent Term Extension (PTE) System

2024年6月17日
Although PTE has been in the Chinese Patent Law since the 4th Amendment of the law came into effect June 1, 2021, we didn’t really know the exact details of how it operated until the Implementation Regulations and Examination Guidelines (“Implementation Regulations”) were finally released in December 2023. New Rules 77-84 in the Implementation Regulations […]

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

2025年9月4日
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]

我們過去活動

Top crossarrow-right